Qynapse
Created in 2015
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
289 3,649Activities
Technologies
Entity types
Location
130 Rue de Lourmel, 75015 Paris, France
Paris
France
Employees
Scale: 11-50
Estimated: 23
SIREN
815093356Engaged corporates
13
5 8Added in Motherbase
6 years, 2 months ago
healthtech Value proposition
The future of neuroimaging is here.
Qynapse offers groundbreaking peace of mind by providing results you can trust.
The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.
Headquartered in France, in the United States and in Canada, the Qynapse team, with our world-renowned team of scientific and clinical partners, is wholly dedicated to aspiring to bring the entire neuroscience community and their patients the clearest, most accurate and reliable predictors and objective measures of devastating CNS disorders such as Alzheimer's disease, multiple sclerosis and Parkinson’s disease.
We are constantly evolving, refining and testing our FDA-cleared and CE-marked neuroimaging software platform, QyScore®, which is powered by proprietary Artificial Intelligence, to provide physicians, pharma researchers and payers a reliable layer of precision when reading an MRI scan. QyPredict®, our predictive research-use-only platform powered by machine learning algorithms, is being designed to transform what we know about CNS disease trajectory, with the potential to dramatically increase the likelihood of a successful clinical trial.
Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system diseases.
Medical device, Neurology, Neuroimaging, Artificial Intelligence, Diagnosis, Prediction, Disease Trajectory, Monitoring, Drug Efficacy, Drug Safety, Personalized Medicine, Clinical Trials, Clinical Research, Central Nervous System, Azheimer's, Parkinson's, Dementia, Multiple Sclerosis, Stroke, and PsychiatryOriginal language
The future of neuroimaging is here.
Qynapse offers groundbreaking peace of mind by providing results you can trust.
The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.
Headquartered in France, in the United States and in Canada, the Qynapse team, with our world-renowned team of scientific and clinical partners, is wholly dedicated to aspiring to bring the entire neuroscience community and their patients the clearest, most accurate and reliable predictors and objective measures of devastating CNS disorders such as Alzheimer's disease, multiple sclerosis and Parkinson’s disease.
We are constantly evolving, refining and testing our FDA-cleared and CE-marked neuroimaging software platform, QyScore®, which is powered by proprietary Artificial Intelligence, to provide physicians, pharma researchers and payers a reliable layer of precision when reading an MRI scan. QyPredict®, our predictive research-use-only platform powered by machine learning algorithms, is being designed to transform what we know about CNS disease trajectory, with the potential to dramatically increase the likelihood of a successful clinical trial.
Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system diseases.
Home - Qynapse - The future of neuroimaging is here
The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust.
https://qynapse.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Eisai Co., Ltd. Pharmaceutical | Eisai Co., Ltd. Pharmaceutical | Other 3 Jul 2024 | | |
 | Dedalus | Other 7 Mar 2023 | | |
 | PariSanté Campus | Other 1 Dec 2024 | | |
 Digital Pharma Lab Pharmaceutical, Health, Business Consulting and Services | Digital Pharma Lab Pharmaceutical, Health, Business Consulting and Services | Other 29 Jun 2023 | | |
 Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP) Health, Medical Practices | Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix (APHP) Health, Medical Practices | Other 24 Mar 2023 | | |
 Amazon Web Services (AWS) IT services, IT Services and IT Consulting | Amazon Web Services (AWS) IT services, IT Services and IT Consulting | Other 27 Jan 2023 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 29 Nov 2022 | | |
 Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Institut du Cerveau – Paris Brain Institute Startup accelerator & VC, Biotechnology Research | Other 24 Mar 2023 | | |
 STATION F Startup accelerator & VC, Software Development | STATION F Startup accelerator & VC, Software Development | Other 16 Nov 2022 | | |
 Agoranov Startup accelerator & VC, Technology, Information and Internet | Agoranov Startup accelerator & VC, Technology, Information and Internet | Not capitalistic Partnership Event 12 Apr 2018 | | |